Neumora moves forward with NLRP3 in obesity after Ventyx's drug failed to deliver weight loss

The "Really Big Neuroscience Company" is now also an obesity drug developer. Neumora is entering the pharma industry's most lucrative sector by advancing an NLRP3 inhibitor days after a competitor said its drug with the ...